In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Amphastar Pharmaceuticals trades significantly below five-method weighted fair value ($26.76 vs. $60.56), implying substantial upside potential amid high confidence. Monte Carlo analysis reveals zero downside risk below current price and a wide value range, indicating volatility but asymmetric upside. Strong liquidity and profitability scores support fundamental stability against valuation dispersion.